NovaBridge appoints Martin Dewhurst. NovaBridge stock sits 79.97 percent below its 52-week high

Published on 10/06/2026 at 06:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NovaBridge held USD 216 million in cash and investments on June 30, 2026. NovaBridge stock sits at USD 156.8 million market value.

NBP, US44975P1030, Illustration mit AI erstellt.

NovaBridge Biosciences (US44975P1030) appointed Martin Dewhurst as an independent director on September 8, 2026, while its stock stood 79.97 percent below its USD 6.79 52-week high at a USD 1.36 latest quote on October 5. The board appointment adds more than 30 years of healthcare leadership experience as the biotechnology company advances its oncology and ophthalmology pipeline, according to NovaBridge Biosciences.

Board expertise meets pipeline execution

Dewhurst joined the Audit and Compensation Committees, giving NovaBridge additional governance experience as it prepares larger clinical programs. The company is developing givastomig for gastric cancer and VIS-101 for retinal vascular disease, with the two programs forming the central investment case presented in September.

At the Cantor Fitzgerald Global Healthcare Conference on September 10, 2026, management said givastomig enrollment had expanded from 17 patients at the July 2025 ESMO meeting and that a Phase 3 study was expected by year-end 2026. Investing.com reported that updated Phase I-B data were planned for ESMO in October.

Cash supports the next milestones

NovaBridge reported USD 216 million in cash and investments as of June 30, 2026, including USD 191 million in cash and cash equivalents and USD 25 million in equity investments. ScanX reported that the balance sheet was debt-free and that management expected the resources to support clinical milestones through 2028.

The latest quarterly report included a USD 0.16 loss per share, according to MarketBeat. That loss contrasts with the companys sizeable liquidity position and leaves clinical execution, financing discipline and future data readouts as the main measurable factors for the equity.

Market value and clinical runway

NBP had a USD 156.8 million market capitalization on October 5, 2026. Its 52-week range was USD 1.31 to USD 6.79, placing the latest USD 1.36 quote USD 0.05 above the low and USD 5.43 below the high.